The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

13 Mar 20264 min read0 viewsOBSERVATIONAL Trial

GIST

RECRUITING · OBSERVATIONAL · Diabetes Mellitus, Type 2 · Enrollment 240 · Sponsor: University of Athens

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Cardiology on 13 Mar 2026. The item focuses on The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT03878706

Open Original Source More Feed Items

Related by Condition/Drug

Endocrine NewsRelated by Conditiondiabetesheart failure

Beyond the Scale: GLP-1 Receptor Agonists and Related Incretin Therapies

Research Highlights • 13 Feb 2026

Endocrine NewsRelated by Conditiondiabetesheart failure

Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do

Research Highlights • 13 Feb 2026

Med News TodayRelated by Conditiondiabetesheart failure

Obesity increases heart failure risk but weight loss can reverse it, study finds

Research Highlights • 01 May 2026

Med News TodayRelated by Conditiondiabetesheart failure

Morning Exercise May Lower Cardiometabolic Risk, Study Suggests

Research Highlights • 24 Mar 2026

Community pharmacy-led diabetes management using continuous glucose monitoring for suboptimally controlled type 2 diabetes: A pilot feasibility study

Research Highlights • 22 May 2026

Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol

Research Highlights • 19 May 2026

Feed Metadata

Source

ClinicalTrials.gov